OBM Transplantation (ISSN 2577-5820) is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc., which covers all evidence-based scientific studies related to transplantation, including: transplantation procedures and the maintenance of transplanted tissues or organs; assimilation of grafted tissue and the reconstitution of removed organs or parts of organs; transplantation of heart, lung, kidney, liver, pancreatic islets and bone marrow, etc. Areas related to clinical and experimental transplantation are also of interest.
OBM Transplantation is committed to rapid review and publication, and we aim at serving the international transplant community with high accessibility as well as relevant and high quality content.
We welcome original clinical studies as well as basic science, reviews, short reports/rapid communications, case reports, opinions, technical notes, book reviews as well as letters to the editor.
Submission Deadline: July 31, 2017 (Open) Submit Now
Nandini Nair, PhD, MD, FSVM, FACC, FACP
Professor of Medicine, Cardiology - Adv HF/MCS/Transplant Cardiology at Texas Tech University Health Sciences Center, Lubbock, TX, USA
Research Interests: antibody mediated rejection; cardiac allograft vasculopathy; role of VADS in diastolic dysfunction; molecular mechanisms underlying heart failure and developing diagnostics and therapeutics
About This Topic
OBM Transplantation publishes peer-reviewed research across the full spectrum of biomedical science, and clinical research and practice in organ transplantation. The journal welcomes experimental, translational and clinical approaches in a special issue directed at Allograft Vasculopathy guest edited by Nandini Nair MD, PhD, FACC, FACP, Texas Tech Health Sciences Center, Lubbock, TX, USA. The journal is seeking original research manuscripts, focused reviews, brief reports, and research letters that address any aspect of allograft vasculopathy, including but not limited to basic mechanisms, epidemiology, pathophysiology, diagnosis, management, and prognosis.
The deadline for submission of manuscripts for consideration for this focus issue is 31st July, 2017. All papers will undergo expedited review with prompt turnaround. All submissions should have a note in the cover letter that they are being submitted for the focus issue.
Please submit manuscripts online via our website. We look forward to receiving your submissions.
Manuscript Submission Information
Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (email@example.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.
Welcome your submission!
Received: 31 May 2017; Published: 28 September 2017; doi: 10.21926/obm.transplant.1703005
Cardiac allograft vasculopathy(CAV) is one of the leading causes of death following the first 5 years after orthotopic heart transplantation(OHT) along with late graft failure( likely secondary to undiagnosed CAV. Currently there is no single medical treatment available for this condition except modification of risk factors and immunosuppres [...]